Absci Corporation (ABSI) is a Vancouver, Washington-based clinical-stage biotech that uses generative AI and a high-throughput synthetic biology lab engine to design biologic drugs, and is now betting its future on ABS-201, an anti-prolactin receptor antibody in development for pattern hair loss and endometriosis. Shares dropped to $7.29 in the current session, a decline of 13.73% from the prior close of $8.45 — a loss of $1.16 per share. The direction is unambiguously lower. The verified catalyst is an analyst price-target reduction issued before the opening bell, layered on top of a broader post-earnings reset triggered by a third-quarter revenue shortfall reported on Nov. 12.
Guggenheim lowered its 12-month target on ABSI to $14 from $15 on Monday while reiterating a Buy rating. The firm said it had updated its model following third-quarter results and a subsequent management conversation, with the cut largely reflecting technical adjustments — most notably a shift to a fully diluted share count in its discounted cash-flow work — rather than a change to the underlying investment thesis.
The note also flagged that the shares could be unusually volatile before and around the December data release. That characterization looks prescient: even at $7.29, the stock sits roughly 92% above the analyst target, which explains why a modest trim to the target has not triggered fresh downgrades but has nonetheless removed a psychological support level for momentum holders.
Today's move is best understood as the third leg of a repricing that began with the third-quarter report. Partner program revenue came in at $0.3 million against expectations near $0.7 million, while net loss widened to $33.3 million, or $0.19 per share — a figure that was broadly in line, meaning the revenue line carried the disappointment. Research and development spending climbed to $23.6 million from $19.2 million a year earlier as ABS-201 costs ramped.
Cash, equivalents, and marketable securities stood at $173.7 million at quarter-end, with management guiding to a runway into the second half of 2028. That is a comfortable cushion for a company burning roughly $35 million a quarter, but it also points to the structural issue: with the stock near a $1.26 billion market cap and trailing revenue of about $1.5 million, valuation rests almost entirely on a single clinical readout. From the $10.12 close on Nov. 11 through today's $7.29, the shares have lost almost 28%.
Absci expects to report 13-week interim proof-of-concept data for ABS-201 in male pattern hair loss in December 2026, with full 26-week data in early 2027 and a Phase 2 endometriosis trial planned for mid-2027. Management has framed the interim cut as a directional signal of biological activity across target-area hair count, total hair count including vellus hairs, and hair width, with pooled safety data. Because the study remains blinded to 26 weeks, the interim dataset will be limited and cohort-skewed — a setup that invites de-risking by investors who would rather re-enter after the event than carry binary exposure through it.
Volume has been running above its three-month average of roughly 3.8 million shares during the selloff, with 5.5 million shares changing hands on Friday alone, suggesting distribution rather than a single thin-print dislocation. The move is company-specific in character but amplified by the stock's high beta of about 2.2 and by sector-wide caution toward unprofitable, AI-adjacent biotech names that had rallied hard this year — ABSI is still up more than 140% year to date.
Technically, the shares have surrendered the 50-day moving average at approximately $9.65 and are pressing toward the $7 area, with the 200-day average near $6.83 as the next meaningful reference. The 52-week range runs from $2.24 to $12.55.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Absci earns 29 out of 100.
The verified news was modest in scale: a $1 reduction to a single analyst's target, with the rating unchanged, on top of a revenue miss that was already three sessions old. Judged against a roughly $1.26 billion valuation, that is not a material fundamental shift. The price move was more notable, running about 2.6 times the stock's typical daily swing of roughly 5.2% over the past 60-odd sessions, though moves of this magnitude or larger have occurred twice in that window. Moderate news plus a somewhat unusual move combines to a low-to-mid score.
All eyes are on the December interim dataset. Investors will want to see a directionally positive hair-growth signal at 13 weeks, with the vellus-inclusive total hair count watched as a potential leading indicator, and pooled safety data free of surprises. A weak or ambiguous signal would likely force another leg of valuation compression given the binary nature of the story; a clean signal could reset expectations toward the 26-week readout in early 2027.
Analyst coverage remains constructive in aggregate — 11 of 12 rated firms sit at Buy or Strong Buy, with a mean target near $13.70 — but targets have been drifting lower. The next quarterly report is expected in the first quarter of 2027, and rising R&D expense tied to the endometriosis program and commercial build-out will be scrutinized. Key risks include clinical failure, further model-driven target cuts, dilution given a share count that has grown nearly 24% year over year, and the tendency of pre-catalyst rallies in micro-cap biotech to unwind quickly.
Tickeron's Trending AI Robots page curates the automated trading strategies delivering the strongest results under present market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the top performers are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup shifts as market conditions evolve. Reviewing it regularly can help you spot approaches aligned with the current environment — explore the page to see which bots are leading today.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for ABSI crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
ABSI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 241 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ABSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 142 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.592). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology